Lorus Therapeutics (APTO) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) from a hold rating to a buy rating in a research report report published on Wednesday morning. They currently have $3.75 price target on the biotechnology company’s stock.

According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “

How to Become a New Pot Stock Millionaire

Other equities research analysts have also recently issued reports about the company. HC Wainwright reiterated a buy rating and set a $6.00 target price (up from $4.00) on shares of Lorus Therapeutics in a research note on Wednesday, December 13th. ValuEngine upgraded Lorus Therapeutics from a strong sell rating to a sell rating in a research note on Tuesday, March 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $5.44.

NASDAQ APTO opened at $3.16 on Wednesday. Lorus Therapeutics has a one year low of $0.78 and a one year high of $3.97.

A hedge fund recently raised its stake in Lorus Therapeutics stock. Acadian Asset Management LLC lifted its holdings in shares of Lorus Therapeutics, Inc. (NASDAQ:APTO) (TSE:APS) by 316.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 44,421 shares of the biotechnology company’s stock after purchasing an additional 33,766 shares during the period. Acadian Asset Management LLC owned about 0.17% of Lorus Therapeutics worth $100,000 at the end of the most recent reporting period. Institutional investors own 1.23% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Lorus Therapeutics (APTO) Rating Increased to Buy at Zacks Investment Research” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/04/01/lorus-therapeutics-apto-rating-increased-to-buy-at-zacks-investment-research.html.

About Lorus Therapeutics

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Get a free copy of the Zacks research report on Lorus Therapeutics (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply